State of the Science: The role of HIPEC in the treatment of ovarian cancer

Gynecol Oncol. 2021 Feb;160(2):364-368. doi: 10.1016/j.ygyno.2020.12.029. Epub 2021 Jan 6.

Authors

Thanh H Dellinger¹, Ernest S Han²

Affiliations

¹ Department of Surgery, Division of Gynecologic Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States of America.
² Department of Surgery, Division of Gynecologic Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States of America. Electronic address: ehan@coh.org.

PMID: 33419611
DOI: 10.1016/j.ygyno.2020.12.029

No abstract available

Keywords: Hyperthermic intraperitoneal chemotherapy (HIPEC); Ovarian cancer.

Publication types

Editorial
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / economics
Carcinoma, Ovarian Epithelial / economics
Carcinoma, Ovarian Epithelial / mortality
Carcinoma, Ovarian Epithelial / pathology
Carcinoma, Ovarian Epithelial / therapy*
Clinical Trials, Phase III as Topic
Cost-Benefit Analysis
Cytoreduction Surgical Procedures
Disease-Free Survival
Female
Hospital Costs
Humans
Hyperthermic Intraperitoneal Chemotherapy / adverse effects
Hyperthermic Intraperitoneal Chemotherapy / economics
Hyperthermic Intraperitoneal Chemotherapy / methods*
Neoadjuvant Therapy / adverse effects
Neoadjuvant Therapy / economics
Neoadjuvant Therapy / methods*
Neoplasm Recurrence, Local / epidemiology*
Neoplasm Recurrence, Local / prevention & control
Ovarian Neoplasms / economics
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Ovarian Neoplasms / therapy*
Ovary / pathology
Ovary / surgery
Patient Selection
Progression-Free Survival
Quality of Life
Randomized Controlled Trials as Topic
Time-to-Treatment